Intersect ENT Inc

Intersect ENT — Investor Presentation (January 2019)

24 slides from Intersect ENT's investor presentation, Jan 7, 2019

  1. Slide 1: Delivering Innovation. Where It's Needed.

    Delivering Innovation. Where It’s Needed. January 2019 Exhibit 99.2

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Certain statements in this presentation constitute “forward-looking statements” within the meaning of the Securities Act of 1933, as amended (the “Securities Act”), and Securities Exchange Act of 1934, as amended (“Exchange Act”), including, without limitation, statements

  3. Slide 3: Intersect ENT Opportunity

    Intersect ENT Opportunity LARGE MARKET $3B+ TAM in US for Chronic Sinusitis GROWTH DRIVERS Expanded Salesforce PRODUCT PIPELINE Enrolling ASCENDTM RCT for Drug-Coated Sinus Balloon FINANCIAL STRENGTH GM 79% (Q318) Cash Balance $104M (Q318**) REVENUE ($M) * Preliminary estimate based on currently ava

  4. Slide 4: Dedicated to Transforming ENT Care in Adults

    Dedicated to Transforming ENT Care 1 in 8 Adults Top 10 Most Costly Condition for US Employers 25 work days lost per year per patient Focus on Chronic Sinusitis Providing innovative, clinically meaningful therapies

  5. Slide 5: PROPEL & SINUVA: Innovative & Clinically Proven

    PROPEL & SINUVA: Innovative & Clinically Proven 1ST DRUG RELEASING IMPLANTS FOR CHRONIC SINUSITIS Local Delivery, Mechanical Spacing, Bioabsorbable Improving Surgical Outcomes Managing Recurrent Disease FAMILY

  6. Slide 6: Portfolio Extending Across Chronic Sinusitis Indications and Care Settings

    OFFICE HOSPITAL / ASC Portfolio Extending Across Chronic Sinusitis Indications and Care Settings Frontal Maxillary Ethmoid

  7. Slide 7: Large Patient Population and Market

    Large Patient Population and Market * Company estimates. ~2M Patients, $3B TAM Early Stage (Office) Advanced (Surgery) Continuing (Office) PATIENTS 800,000 540,000 635,000 TAM $1.1B $0.8B $1.3B Addressing CS Across the Continuum of Care

  8. Slide 8: Commitment to Evidence-Based Innovation

    Commitment to Evidence-Based Innovation 14 Prospective Clinical Studies 40 Centers in US > 900 Patients Pilot (PROPEL) 43 Patients 4 Sites ADVANCE 50 Patients 7 Sites ADVANCE II 105 Patients 11 Sites PROGRESS (mini) 80 Patients 11 Sites PROGRESS (Contour) 80 Patients 12 Sites EXCEED (Contour) 15 Pat

  9. Slide 9: PROPEL Family: Improving Surgical Outcomes

    FAMILY Improving Surgical Outcomes

  10. Slide 10: PROPEL Family Surgical Products to Improve Outcomes

    PROPEL Family 3 Surgical Products to Improve Outcomes Advanced into Surgically Enlarged Sinus Cavity OPENS Self-Expanding Implant Conforms to and Holds Open Sinus DELIVERS Sustained, Targeted Delivery of Steroid Over 30 Days MAINTAINS Opening by Reducing Post-Operative Inflammation and Scarring MULT

  11. Slide 11: PROPEL and PROPEL Mini Clinically Proven Outcomes

    Approved for Placement in Ethmoid Sinus Only Device Used in Sinus Surgery Backed by Level 1a Evidence 35% Reduction in Post-Operative Intervention PROPEL and PROPEL Mini Clinically Proven Outcomes Meta-analysis: Han JK, Marple BF, Smith TL et al. Int Forum Allergy Rhinol, Vol. 2, No. 4, July/August

  12. Slide 12: PROPEL Contour Clinically Proven Outcomes

    p=0.1094 FRONTAL AND MAXILLARY SINUSES p=0.0023 P<0.0001 p=0.0078 PROPEL Contour Clinically Proven Outcomes CONTOUR STUDY 80 Patient Prospective, Randomized, Blinded, Multi-Center Trial Post-operative Intervention* Oral Steroid Intervention** Occlusion/ Restenosis** 65% 35% 63% Surgical Intervention

  13. Slide 13: Growth Drivers and Continuing Commercial Traction

    GROWTH DRIVERS Leverage expanded salesforce (~140 reps) Continue PROPEL Contour Roll-out Add New Accounts Expand Physician Usage PROPEL FAMILY Continuing Commercial Traction 1 in 8 Sinus Surgeries ~ 50% of Accounts TODAY 1 in 3 ENTs ~ 280,000 Patients Treated As of Q4, 2018

  14. Slide 14: Focus on Higher Quality of Care with Lower Overall Cost

    Focus on Higher Quality of Care with Lower Overall Cost COST EFFECTIVENESS STUDY1 Placement of PROPEL following FESS “is a cost-effective intervention for preventing a postoperative intervention within 60 days after surgery.” BUDGET IMPACT MODEL2 Use of PROPEL is “expected to save the plan money” Re

  15. Slide 15: SINUVA (mometasone furoate) sinus implant

    (mometasone furoate) snus implant Designed to

  16. Slide 16: Designed for Patients Who Have Had Prior Surgery

    Designed for Patients Who Have Had Prior Surgery Dilates Obstructed Cavity Delivers~4x Steroid (vs. PROPEL) Over 90 Days 100% Patient Compliance OVERVIEW ETHMOID SINUS SINUVA Office Treatment for Recurrent CRS/Polyps Ethmoid Sinus Pre-implant Immediately Post-implant 6 Weeks Post-implant

  17. Slide 17: SINUVA Clinically Proven Outcomes

    NDA Approved December 2017 4 Studies Conducted in over 400 patients Targeted Commercial Launch Q218 SINUVA Clinically Proven Outcomes ETHMOID SINUS 300 Patient Prospective, Randomized, Blinded, Multi-Center Trial CO-PRIMARY and KEY SECONDARY ENDPOINTS MET Reduction in Bilateral Polyp Grade (p=0.0073

  18. Slide 18: SINUVA Reduction in Polyps and Sinus Obstruction

    SINUVA Reduction in Polyps and Sinus Obstruction ENDOSCOPIC OUTCOMES * p-value < 0.0001 BILATERAL POLYP GRADE ETHMOID SINUS OBSTRUCTION Treatment Control Change from Baseline 0% -5% -10% -15% -20% -25% -30% Data on file, Intersect ENT. RESOLVE II CR-00014 Rev. 1.0 January 2018. Grading by Clinical I

  19. Slide 19: SINUVA Reimbursement Basics

    SINUVA Reimbursement Basics *Ernst FR, Imhoff RJ, DeConde, Manes RP. Steroid-Eluting Sinus Implant Versus Revision Surgery for Patients with Recurrent Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): An Economic model. Poster presentation at 2018 International Society of Pharmacoeconomics and Outc

  20. Slide 20: SINUVA Foundation Established in 2018

    SINUVA Foundation Established in 2018 Positive Clinical Experience ~1200 Patients Treated ~500 Physicians Top 6 Commercial Payors Providing Access Established Network of SPs & SDs Prior-Authorizations in <30 Days Increasing Use of Buy and Bill ~25% Salesforce Growth in ‘18 Expanded Reimbursement Tea

  21. Slide 21: ASCEND Drug Coated Balloon

    ASCEND Drug Coated Balloon Emerging Pipeline Product Conducting Clinical Study of Investigational ASCEND Mometasone Furoate Drug Coated Balloon (DCB) Designed to Improve Peripheral Sinus Patency Regulatory Path: PMA MARKET OPPORTUNITY Focus primarily on office setting of care Expands product offerin

  22. Slide 22: Emerging Opportunity Outside the US

    Emerging Opportunity Outside the US ~540K FESS / Year ~450K FESS / Year ~250K FESS / Year OUS TO CONTRIBUTE TO LONG-TERM GROWTH Establishing Germany as European beachhead Expanding to Switzerland, Austria and England Pursuing Japan Shonin Regulatory Approval

  23. Slide 23: 2019 Outlook

    REVENUE ($M) 2019 Outlook COMMERCIAL Leverage 2018 Salesforce Expansion Ramp SINUVA REIMBURSE-MENT Streamline Product Access Secure Product Specific J Code to Support SINUVA Long-term * Preliminary estimate based on currently available information. Has not been audited or reviewed by our independent

  24. Slide 24: Intersect ENT: Delivering Innovation. Where It's Needed.

    ® % intersect ENT DELIVERING INNOVATION. WHERE IT’S NEEDED.

Intersect ENT — Investor Presentation (January 2019) on 6ix